The initial experience of COVID-19 vaccination from a tertiary care centre of India

Abstract

To the Editor Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ''COVAXIN'' in collaboration with the Indian council of medical research (ICMR) on 3rd January 2021 for emergency use along with the "Covishield" Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India... *The Safdarjung COVID-19 Vaccination group: KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine)

Influence of the Peltzman effect on the recurrent COVID-19 waves in Europe

“…COVID-19 vaccination-The development and the roll-out of safe and efficient COVID-19 vaccines have been an effective weapon in the global fight against the COVID-19 pandemic triggered by the novel coronavirus SARS-CoV-2. 6 Recent reports by Public Health England suggest that both the Pfizer-BioNTech and Oxford-AstraZeneca vaccines effectively reduce COVID-19 infections among older people aged 70 years and over. In the older age groups (80 years and above), data suggest that a single dose of either vaccine is more than 80% effective at preventing hospitalisation and lowers the risk of serious illness with the Pfizer-BioNTech vaccine able to reduce mortality from COVID-19 by more than 80%.…”

Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challenges

“…No significant difference or serious adverse events were reported in this study in any of the groups [168,169]. Another report from a tertiary care center in India suggested that Covaxin is safe and effective, and the adverse effects are minor in this vaccine appearing only in 15 people out of 1322 [170].…”

Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

“…63 Another inactivated virusbased COVID-19 vaccine known as Covaxin (BBV152) has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research. 64 This whole-virion inactivated SARS-CoV-2 vaccine produced in Vero cells was prepared with a Toll-like receptor7/8 agonist molecule adsorbed to alum. The safety and tolerability of Covaxin were revealed in the phase 1 vaccine trial, which evaluated 375 participants in four groups.…”